Skip to Content

Not an actual patient.

Revance Aesthetics is building the prestige market for aesthetics comprised of expertly created products and services that are available exclusively in select practices who produce exceptional consumer experiences and outcomes.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.

Aesthetics

Facts, Figures & Trends

#1 + #2

Neuromodulators are the most performed minimally invasive cosmetic procedures, followed by dermal fillers1

10.4+ million

Total neuromodulator and dermal fillers procedures performed in 2019 1

~2.2 billion

2019 U.S. facial aesthetics market (neuromodulators and dermal fillers)2

The first designer hyaluronic acid (HA) filler

RHA® - resilient hyaluronic acid – is the latest advancement in HA filler science. The RHA® Collection of fillers are the first and only resilient HA fillers designed for facial dynamics and formulated to be more like natural HA found in the skin.

Learn More

DaxibotulinumtoxinA for Injection

Our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, is aiming to establish a new, premium, long-lasting neuromodulator category.

Learn More

Unique financial technology platform designed to transform existing payment processing ecosystems and improve both aesthetic economics and patient experiences.

Learn More

References

  1. The American Society of Plastic Surgeons. 2019 Plastic Surgery Statistic Report. Available at: https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf. Accessed July 2020
  2. Based on estimates from the USB Specialty Pharmaceuticals Handbook 2018
Back to top